| Target | Sensitivity | Specificity | False positive in |
| Nuclear morphology abnormalities | 59 to 69 percent | 73 to 93 percent | |
| Cytokeratin 20 | 78 to 87 percent | 55 to 80 percent | Urinary tract infection, calculi, post-BCG |
| Telomerase | 70 to 100 percent | 60 to 70 percent | Infection |
| Microsatellite DNA | 72 to 97 percent | 80 to 100 percent | BPH, inflammation |
| Chromosomal abnormalities (chromosomes 3, 7, 17, and 9p21) | 69 to 87 percent | 89 to 96 percent | BPH, inflammation, hematuria |
| Carcinoembryonic antigen (CEA), mucoproteins | 70 to 80 percent | 60 to 70 percent | BPH, inflammation, hematuria |
| DD23 antibody | 70 to 87 percent | 60 percent | |
| Lewis X antigen | 80 to 85 percent | 80 to 85 percent | BPH |
